Gilead Sciences (GILD) Tops Q3 EPS by 38c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $146.85 +1.82%
Revenue Growth %: -0.4%
Financial Fact:
Net income attributable to Gilead: 3.33B
Today's EPS Names:
AEHR, VFS, CMTL, More
Revenue Growth %: -0.4%
Financial Fact:
Net income attributable to Gilead: 3.33B
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.29, $0.38 better than the analyst estimate of $1.91. Revenue for the quarter came in at $7.1 billion versus the consensus estimate of $6.81 billion.
GUIDANCE:
Gilead Sciences sees FY2023 EPS of $6.65-$6.85, versus the consensus of $6.25. Gilead Sciences sees FY2023 revenue of $26.7-26.9 billion, versus the consensus of $25.3 billion.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Levi (LEVI) Tops Q3 EPS by 12c; raises guidance
- MicroVision reaffirms 2026 revenue guidance, projects double in 2027
- Gilead Sciences (GILD) PT Lowered to $163 at Morgan Stanley
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
